657 completed. 657 Phase 1, 211 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 657 | Completed 657 |
| Phase 2 | 211 | Completed 211 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers. BAY 3389934, Matching Placebo / Diluent - Sepsis Associated Disseminated Intravascular Coagulation (DIC) | Phase 1 | Completed | Bayer | 16 | 2025-09-22 | 2026-06-05 |
| A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization Motixafortide, G-CSF - Multiple Myeloma | Phase 1 | Completed | Washington University School of Medicine | 20 | 2024-10-31 | 2025-08-29 |
| Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin VMX-C001, Rivaroxaban, UFH - Coagulation Disorder | Phase 1 | Completed | VarmX B.V. | 16 | 2024-08-14 | 2026-05-11 |
| Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Elvira Umyarova | 3 | 2024-03-05 | 2026-07-01 |
| Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant VMX-C001, Placebo, Rivaroxaban 20 mg Oral Tablet - Coagulation Disorder | Phase 1 | Completed | VarmX B.V. | 40 | 2024-02-21 | 2026-09-09 |
| Doxil/Caelyx BE Study DOXIL/CAELYX - Ovarian Cancer, AIDS-related Kaposi Sarcoma | Phase 1 | Completed | Baxter Healthcare Corporation | 36 | 2023-12-16 | 2025-06-05 |
| A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China Maplirpacept - Non-Hodgkin Lymphoma, Multiple Myeloma | Phase 1 | Completed | Pfizer | 10 | 2023-06-28 | 2024-11-20 |
| A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects HLX15, US-sourced DARZALEX®, CN-sourced DARZALEX® - Multiple Myeloma | Phase 1 | Completed | Shanghai Henlius Biotech | 172 | 2023-01-31 | 2024-06-28 |
| Ascending Dose Study of FrontlineODP™ Spray Dried Plasma Autologous Spray Dried Plasma - Coagulopathy, Hemorrhage | Phase 1 | Completed | Velico Medical | 24 | 2022-12-01 | 2025-09-18 |
| A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies maplirpacept (PF-07901801) - Lymphoma, Multiple Myeloma | Phase 1 | Completed | Pfizer | 7 | 2022-11-02 | 2024-11-06 |
| BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma LCAR-BCDR cells product - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | Shanghai Changzheng Hospital | 24 | 2022-09-01 | 2026-09-22 |
| Study of 3D189 in Patients With Hematologic Malignancies 3D189 - Acute Leukemia, Multiple Myeloma | Phase 1 | Completed | 3D Medicines | 16 | 2022-08-01 | 2026-09-09 |
| Phase I Trial of GR1803 Injection in Patients With RRMM GR1803 injection - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 76 | 2022-05-27 | 2025-08-05 |
| A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma XmAb24306, Daratumumab - Multiple Myeloma | Phase 1 | Completed | Genentech, Inc. | 18 | 2022-04-28 | 2025-02-17 |
| Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# IBI346 - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | The First Affiliated Hospital of Soochow University | 6 | 2022-04-27 | 2023-07-27 |
| Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE INZ-701 - ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum | Phase 1 / Phase 2 | Completed | Inozyme Pharma | 10 | 2022-04-11 | 2026-10-13 |
| Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma ORIC-533 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Completed | ORIC Pharmaceuticals | 31 | 2022-01-06 | 2025-03-20 |
| FT576 in Subjects With Multiple Myeloma FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine - Multiple Myeloma, Myeloma | Phase 1 | Completed | Fate Therapeutics | 31 | 2021-11-10 | 2025-12-12 |
| Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects VMX-C001, Placebo, Apixaban - Coagulation Disorder | Phase 1 | Completed | VarmX B.V. | 105 | 2021-10-29 | 2023-06-02 |
| A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma TTI-622, Daratumumab Hyaluronidase-fihj - Multiple Myeloma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 7 | 2021-10-28 | 2026-07-06 |
Showing 20 of 657. Sign in to see all of them.
Multiple Myeloma (550) · Lymphoma, Non-Hodgkin (165) · Leukemia, Lymphocytic, Chronic, B-Cell (157) · Lymphoma, Follicular (141) · Lymphoma, Mantle-Cell (137) · Waldenstrom Macroglobulinemia (130) · Lymphoma, B-Cell, Marginal Zone (129) · Lymphoma, Large B-Cell, Diffuse (123) · Hodgkin Disease (122) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (122) · Lymphoma (116) · Burkitt Lymphoma (105) · Neoplasms, Plasma Cell (104) · Lymphoma, Large-Cell, Immunoblastic (90) · Leukemia (87)
Hemic and Lymphatic Diseases (657) · Cardiovascular Diseases (656) · Vascular Diseases (654) · Hemorrhagic Disorders (651) · Hematologic Diseases (645) · Neoplasms by Histologic Type (634) · Immune System Diseases (633) · Blood Protein Disorders (632) · Immunoproliferative Disorders (630) · Paraproteinemias (626) · Lymphoproliferative Disorders (625) · Neoplasms (606) · Neoplasms, Plasma Cell (530) · Lymphatic Diseases (261)
Dexamethasone (124) · Bortezomib (76) · Lenalidomide (75) · Cyclophosphamide (60) · Calcium Dobesilate (49) · Melphalan (44) · carfilzomib (37) · fludarabine phosphate (33) · pomalidomide (32) · Peripheral Blood Stem Cell Transplantation (29) · Rituximab (28) · Filgrastim (26) · fludarabine (21) · Tacrolimus (18) · ixazomib (18)
National Cancer Institute (NCI) (50) · Mayo Clinic (24) · Celgene (22) · Memorial Sloan Kettering Cancer Center (17) · Fred Hutchinson Cancer Center (16) · M.D. Anderson Cancer Center (15) · Millennium Pharmaceuticals, Inc. (15) · Novartis Pharmaceuticals (12) · Amgen (10) · City of Hope Medical Center (10) · Sanofi (10) · Janssen Research & Development, LLC (9) · Merck Sharp & Dohme LLC (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · Janssen Pharmaceutical K.K. (8)
United States (514) · France (41) · Canada (40) · Spain (37) · Australia (33) · Italy (33) · Germany (30) · United Kingdom (29) · Japan (24) · China (16) · Netherlands (15) · South Korea (14) · Denmark (12) · Belgium (8) · Israel (8)
Paul Richardson, MD (4) · Shaji Kumar (4) · Angela Dispenzieri, MD (3)
PMID 37022569, PMID 28803351, PMID 32499241, PMID 19238148, PMID 26370838, PMID 26943915, PMID 33980831, PMID 34398557, PMID 40000533, PMID 40826257, PMID 42287565, PMID 10552943, PMID 10564685, PMID 10764422, PMID 12171484, PMID 12473574, PMID 12752100, PMID 14767498, PMID 15241836, PMID 15466934, PMID 15570084, PMID 15902208, PMID 15958804, PMID 16061911, PMID 17020988, PMID 17312328, PMID 17975015, PMID 18032762, PMID 18032763, PMID 18202410, PMID 18327587, PMID 18418404, PMID 18463792, PMID 18470481, PMID 18768528, PMID 18974373, PMID 19179301, PMID 19182205, PMID 19188182, PMID 19826119, PMID 19901123, PMID 20053869, PMID 20133895, PMID 20508619, PMID 20595516, PMID 20661232, PMID 20733120, PMID 20864577, PMID 20952687, PMID 21030558
P30CA015083 (13), 2019 (7), P30CA006973 (7), P30CA016058 (7), U01CA076576 (7), 2018 (6), P30CA015704 (6), 2015 (5), 2016 (5), P30CA016672 (5), P30CA022453 (5), U01CA062502 (5), U01CA062505 (5), U01CA069912 (5), 2014 (4)